🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Non-small-cell Lung Cancer Patients

Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients NCT03803787Phase 22 sites📍 Mexico City📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Inhaled budesonide Pathological Response After Neoadjuvant Treatment on NSCLC NCT05167487n/a17 sites📍 A Coruña📍 Alicante📍 Badalona Fundación GECP · Tests: Cisplatin, Carboplatin TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies NCT06484816Phase 11 site📍 Hangzhou Shenzhen TargetRx Co., Ltd. · Tests: TGRX-1942 A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC NCT06745882Phase 211 sites📍 Tampa📍 Baton Rouge📍 Baltimore H. Lee Moffitt Cancer Center and Research Institute · Tests: Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer NCT06205927Phase 21 site📍 Shanghai Jian Chen · Tests: Standard carbon ion beam radiotherapy, Carbon ion beam radiotherapy simultaneously dose boost Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy NCT05398094Phase 220 sites📍 Alicante📍 Badalona📍 Barcelona Fundación GECP · Tests: Sotorasib T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors NCT07250386Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural) AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389Phase 31 site📍 Shanghai Akeso · Tests: Ivonescimab, docetaxel, Placebo, docetaxel Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC NCT07492342Phase 23 sites📍 Beijing📍 Guangzhou📍 Zhejiang Jianxing He · Tests: fulzerasib Cognitive Screening in Lung Cancer Patients NCT06727370n/a1 site📍 Milan European Institute of Oncology Osimertinib for Advanced EGFR-positive NSCLC Patients NCT05037331n/a1 site📍 Singapore National University Hospital, Singapore Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) NCT07154706Phase 333 sites📍 Los Angeles📍 Orange📍 Washington D.C. Nuvation Bio Inc. · Tests: Taletrectinib, Placebo Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) NCT07460999NA5 sites📍 Copenhagen📍 Copenhagen📍 Næstved Zealand University Hospital · Tests: Singing training (Singing for Lung Health (SLH)), Control group: Usual care RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813Phase 21 site📍 Beijing TYK Medicines, Inc · Tests: TY-9591, Osimertinib Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations NCT05445791Phase 31 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Metformin Hydrochloride, Placebo Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites📍 Ferrol📍 Alicante📍 Badalona Fundación GECP · Tests: Durvalumab Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade NCT07130032Phase 21 site📍 Saint Petersburg EuroCityClinic LLC · Tests: reICB regimen (NSCLC), reICB regimen (melanoma) Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031Phase 21 site📍 Beijing Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0015 Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC NCT03872661Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: IBI308, Bevacizumab, Pemetrexed, Carboplatin, Thoracic surgery Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer NCT05292521NA1 site📍 Buffalo Roswell Park Cancer Institute · Tests: Best Practice, Informational Intervention, Questionnaire Administration Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients NCT06311981Phase 21 site📍 Shanghai Jian Chen · Tests: carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC NCT06769295Phase 21 site📍 Chengdu Sichuan University · Tests: AK112 A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC NCT06754930Phase 1, Phase 21 site📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-1826, SHR-1316, SHR-9839, SHR-8068, Ametinib mesylate A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631Phase 19 sites📍 Princeton📍 Montreal📍 Odense C Novartis Pharmaceuticals · Tests: 68Ga-NNS309, 177Lu-DFC413
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy